We introduce ourselves
Founded in 2002, Alnylam is the pioneer and leader in RNA interference (RNAi) therapeutics, a new category of medicines based on Nobel-Prize winning Science. RNAi therapeutics target the genetic causes of a disease rather than its symptoms, by “turning off” harmful proteins at their source. Using RNAi, we can silence any gene in the genome, and deliver products that have remarkable potency and durability. If the disease is like a leaking tap, then RNAi provides a new way of fixing the leak, rather than just mopping up the floor. This approach has the potential to transform the care of patients with genetic and other diseases in Europe. In 2018, we successfully launched the world’s first RNAi therapeutic to help patients suffering from the rare condition of hereditary ATTR amyloidosis and we have followed this with the launch of two further first-in-class medicines. We are striving to submit a further eight new drug applications by 2025 – all for conditions with limited or no treatment options across five therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, central nervous system (CNS) and ocular diseases. Our commitment to Europe is essential to our commercial success. We opened our first office in Europe in 2016 and for the past five years, we have partnered with healthcare experts and research organisations in the region. We currently have 11 offices and over 170 active clinical trial sites across Europe.